SEC22A: A Potential Drug Target and Biomarker for Vesicle Trafficking Protein-Like 2 (VTPL2)

Target Name: SEC22A

NCBI ID: G26984

SEC22A

SEC22A: A Potential Drug Target and Biomarker for Vesicle Trafficking Protein-Like 2 (VTPL2)

Secretory Endoplasmic Reticulum (SER) vesicle trafficking protein-like 2 (VTPL2) is a protein that plays a crucial role in the regulation of vesicle traffic and trafficking in the ER. It is a 22-kDa protein that contains a N-terminal transmembrane domain , a catalytic domain, and a C-terminal cytoplasmic domain. VTPL2 functions as a scaffold protein, helping to maintain the structural integrity of vesicles and to regulate their trafficking to and from the ER. It is also involved in the regulation of cellular signaling pathways , including the Wnt signaling pathway.

Recent studies have identified VTPL2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The potential targets of VTPL2 include inhibiting its intracellular signaling, modulating its expression levels, and altering its localization to specific cellular compartments..

One of the main potential drug targets for VTPL2 is inhibiting its role in the regulation of vesicle trafficking. VTPL2 is known to play a key role in the formation and maintenance of vesicles, which are specialized structures that transport proteins and other molecules across the ER membrane . It is thought to regulate the trafficking of proteins to and from the ER by interacting with specific protein partners, including the transmembrane protein, Transmembrane protein-like 2 (TMC2).

Inhibiting VTPL2 activity to manipulate vesicle trafficking has been shown to be a promising strategy for the treatment of various diseases. For example, studies have shown that inhibiting VTPL2 can lead to the formation of large vesicles that disrupt the proper delivery of proteins to the ER, leading to the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Another potential drug target for VTPL2 is modulating its expression levels. VTPL2 is a nuclear protein that is predominantly expressed in the ER, but can also be found in other cellular compartments, including the cytoplasm. It is thought to play a role in regulating the levels of other proteins in the ER, including the transcription factor, p53. Therefore, modulating VTPL2 expression levels may be a promising strategy for the treatment of diseases that are characterized by the over-expression of specific genes.

Alterating VTPL2 localization to specific cellular compartments is also a potential drug target for the protein. VTPL2 is thought to play a role in regulating the trafficking of proteins to and from different cellular compartments, including the ER, the cytoplasm, and the endoplasmic risk particle( endoplasmic reticulum). Therefore, inhibiting VTPL2 localization to specific cellular compartments, such as the ER, may be a promising strategy for the treatment of diseases that are characterized by the mislocalization of proteins to different cellular compartments.

In conclusion, SEC22A (SEC22 vesicle trafficking protein-like 2) is a protein that plays a crucial role in the regulation of vesicle traffic and trafficking in the ER. It is a 22-kDa protein that contains a N-terminal transmembrane domain, a catalytic domain, and a C-terminal cytoplasmic domain. VTPL2 functions as a scaffold protein, helping to maintain the structural integrity of vesicles and to regulate their trafficking to and from the ER. Recent studies have identified VTPL2 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The potential targets of VTPL2 include inhibiting its intracellular signaling, modulating its expression levels, and altering its localization to specific cellular compartments. Further research is needed to fully understand the role of VTPL2 in

Protein Name: SEC22 Homolog A, Vesicle Trafficking Protein

Functions: May be involved in vesicle transport between the ER and the Golgi complex

The "SEC22A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC22A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets